Akari Therapeutics Plc

1.59-0.0527-3.21%Vol 128.30K1Y Perf -23.56%
Jul 27th, 2021 14:44 DELAYED
BID1.58 ASK1.59
Open1.62 Previous Close1.64
Pre-Market1.66 After-Market-
 0.02 1.22%  - -
Target Price
5.00 
Analyst Rating
Strong Buy 1.00
Potential %
220.51 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap75.55M 
Earnings Rating
Neutral
Price Range Ratio 52W %
6.00 
Earnings Date
7th Sep 2021

Today's Price Range

1.561.63

52W Range

1.424.21

5 Year PE Ratio Range

-1.60-1.50

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.00%
1 Month
-6.82%
3 Months
-29.91%
6 Months
-44.78%
1 Year
-23.56%
3 Years
-18.00%
5 Years
-81.57%
10 Years
-

TickerPriceChg.Chg.%
AKTX1.59-0.0527-3.21
AAPL147.13-1.8600-1.25
GOOG2 733.98-58.9100-2.11
MSFT286.43-2.6200-0.91
XOM57.77-0.7100-1.21
WFC45.100.09000.20
JNJ172.380.51000.30
FB367.01-5.4500-1.46
GE13.150.23001.78
JPM151.50-0.1500-0.10
Earnings HistoryEstimateReportedSurprise %
Q01 2021--0.15-
Q04 2020--0.22-
Q03 20200.000.04-
Q02 20200.00-0.28-
Q01 20200.00-0.13-
Q04 20190.00-0.37-
Q03 20190.00-0.14-
Q02 20190.00-0.26-
Earnings Per EndEstimateRevision %Trend
12/2020 QR0.00--
12/2020 QR0.00--
12/2021 FY0.00100.00Positive
12/2022 FY-0.01--
Next Report Date7th Sep 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume128.30K
Shares Outstanding47.60M
Trades Count346
Dollar Volume788.40K
Avg. Volume337.93K
Avg. Weekly Volume103.14K
Avg. Monthly Volume116.73K
Avg. Quarterly Volume421.93K

Akari Therapeutics Plc (NASDAQ: AKTX) stock closed at 1.64 per share at the end of the most recent trading day (a 1.23% change compared to the prior day closing price) with a volume of 88.73K shares and market capitalization of 75.55M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. Akari Therapeutics Plc CEO is Clive Richardson.

The one-year performance of Akari Therapeutics Plc stock is -23.56%, while year-to-date (YTD) performance is -11.35%. AKTX stock has a five-year performance of -81.57%. Its 52-week range is between 1.42 and 4.21, which gives AKTX stock a 52-week price range ratio of 6.00%

Akari Therapeutics Plc currently has a PE ratio of -1.50, a price-to-book (PB) ratio of 16.52, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -207.92%, a ROC of -667.23% and a ROE of -653.52%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Akari Therapeutics Plc, there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Akari Therapeutics Plc’s next earnings report date is 07th Sep 2021.

The consensus rating of Wall Street analysts for Akari Therapeutics Plc is Strong Buy (1), with a target price of $5, which is +220.51% compared to the current price. The earnings rating for Akari Therapeutics Plc stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Akari Therapeutics Plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Akari Therapeutics Plc has a Sell technical analysis rating based on Technical Indicators (ADX : 17.50, ATR14 : 0.08, CCI20 : -58.52, Chaikin Money Flow : -0.16, MACD : -0.04, Money Flow Index : 51.55, ROC : 0.61, RSI : 43.32, STOCH (14,3) : 26.67, STOCH RSI : 0.64, UO : 41.39, Williams %R : -73.33), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Akari Therapeutics Plc in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Akari Therapeutics Plc

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. The firm earns majority of its revenues from United Kingdom. It operates mainly in United States and United Kingdom.

CEO: Clive Richardson

Telephone: +44 2080040270

Address: 75/76 Wimpole Street, London W1G 9RT, , GB

Number of employees: 10

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

83%17%

Bearish Bullish

57%43%

Bearish Bullish

70%30%

News

Stocktwits